If you have been reading about GHRH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
=== The Buck Institute for Research on Aging === In November 2016, Verdin became president and CEO of the Buck Institute for Research on Aging. The Buck Institute is the first independent research center focused solely on aging. As of 2022, it had an operating budget of $65 million a year and around 300 employees. The Buck's first human clinical trial, Buck Institute Ketone Ester (BIKE), was announced in 2023. In 2025, Verdin was named a scientific ambassador for Alliance for Longevity Science, Arts & Entertainment (ALSAE), a partner organization of the Buck Institute.
== Signs and symptoms == The lesion is usually painless. The usual appearance is of two excess tissue folds in alveolar vestibule/buccal sulcus, with the flange of the denture fitting in between the two folds. It may occur in either the maxillary or mandibular sulci, although the latter is more usual. Anterior locations are more common than posterior. Less commonly there may be a single fold, and the lesion may appear on the lingual surface of the mandibular alveolar ridge. The swelling is firm and fibrous, with a smooth, pink surface. The surface may also show ulceration or erythema. The size of the lesion varies from less than 1 cm to involving the entire length of the sulcus.
=== Anti-cancer treatment === SAM has recently been shown to play a role in epigenetic regulation. DNA methylation is a key regulator in epigenetic modification during mammalian cell development and differentiation. In mouse models, excess levels of SAM have been implicated in erroneous methylation patterns associated with diabetic neuropathy. SAM serves as the methyl donor in cytosine methylation, which is a key epigenetic regulatory process. Because of this impact on epigenetic regulation, SAM has been tested as an anti-cancer treatment. In many cancers, proliferation is dependent on having low levels of DNA methylation. In vitro addition in such cancers has been shown to remethylate oncogene promoter sequences and decrease the production of proto-oncogenes. In cancers such as colorectal cancer, aberrant global hypermethylation can inhibit promoter regions of tumor-suppressing genes. Contrary to the former information, colorectal cancers (CRCs) are characterized by global hypomethylation and promoter-specific DNA methylation.
Sources: en.wikipedia.org
In 2011, Sá Fernandes said that he had a solid accusation, but did not want to turn Dias into a "scapegoat," and in case there was any doubt, he would not ask for his conviction."We are sure that the defendant consummated the crime [of kidnapping] (...) doesn't have the slight sign of regret. Acts with total indifference (...) It was proven that the defendant kidnapped Rui Pedro, taking him to Lustosa against the minor's parent's will. (...) I evaluated the evidence and reached the conclusion that the defendant is the author of the facts judged here. I ask for justice and humanity for the case's resolution. In the end of this process there is sorrow and anguish for not finding out what happened to Pedro. The Public Prosecution asks for justice and waits for it to be done" - Public Prosecution, 2012When Dias' arrest was definitely announced, Manuel Mendonça said that the now convicted had multiple opportunities to tell what he did to Mendonça, even by anonymous letter and highlighted that he did not want his conviction. After being freed, Dias said in 2018 that he was a victim of "a great injustice" and blamed Mendonça's family for his jail time.
Astrocytes are a sub-type of glial cells in the central nervous system. They are also known as astrocytic glial cells. Star-shaped, their many processes envelop synapses made by neurons. In humans, a single astrocyte can interact with up to two million synapses at a time. Astrocytes are classically identified histologically; many of these cells express glial fibrillary acidic protein (GFAP), a type III intermediate filament protein.
11-Hydroxy-Δ9-tetrahydrocannabinol (11-OH-Δ9-THC, alternatively numbered as 7-OH-Δ1-THC), usually referred to as 11-hydroxy-THC within cannabis culture, is the main active metabolite of tetrahydrocannabinol (THC), the major psychoactive substance in cannabis. After cannabis consumption, THC is metabolized inside the body by cytochrome P450 enzymes such as CYP2C9 and CYP3A4 into 11-hydroxy-THC and then further metabolized by dehydrogenase and CYP2C9 enzymes to form 11-nor-9-carboxy-THC (THC-COOH), which is inactive at the CB1 receptors; and further glucuronidated to form 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid glucuronide (Δ9-THC-COOH-glu) in the liver, from where it is subsequently excreted through feces and urine. Both metabolites can be assayed in drug tests. 11-hydroxy-THC is formed after human consumption of THC containing products regardless of administration route, although levels of 11-hydroxy-THC are typically higher when cannabis products are eaten instead of inhaled.
Sources: en.wikipedia.org
When applied to the tongue or to shaven skin, brilliant blue FCF can be absorbed directly into the bloodstream. However, in experiments with rodents, it was found that it is poorly absorbed from the gastrointestinal tract, and 95% of the ingested dye can be found in the feces.
=== Requests for a moratorium on military use === A number of anti-war activists specializing in international humanitarian law have questioned the legality of the continued use of depleted uranium weapons, highlighting that the effects may breach the principle of distinction (between civilians and military personnel). Some states and the International Coalition to Ban Uranium Weapons, a coalition of more than 155 non-governmental organizations, have asked for a ban on the production and military use of depleted uranium weapons. The European Parliament has repeatedly passed resolutions requesting an immediate moratorium on the further use of depleted uranium ammunition, but France and Britain – the only European states that are permanent members of the United Nations Security Council—have consistently rejected calls for a ban, maintaining that its use continues to be legal, and that the health risks are unsubstantiated. In 2007, France, Britain, the Netherlands, and the Czech Republic voted against a United Nations General Assembly resolution to hold a debate in 2009 about the effects of the use of armaments and ammunitions containing depleted uranium. All other European Union nations voted in favour or abstained.
Sitagliptin (FDA approved in 2006, and marketed by Merck & Co. as Januvia) Vildagliptin (EU approved in 2007, and marketed in the EU by Novartis as Galvus) Saxagliptin (FDA approved in 2009, and marketed as Onglyza) Linagliptin (FDA approved in 2011, and marketed as Tradjenta by Eli Lilly and Company and Boehringer Ingelheim) Gemigliptin (approved in Korea in 2012, and marketed by LG Life Sciences as Zemiglo, among other names) Anagliptin (approved in Japan as Suiny in 2012; marketed by Sanwa Kagaku Kenkyusho Co., Ltd. and Kowa Company, Ltd.) Teneligliptin (approved in Japan as Tenelia in 2012) Alogliptin (FDA approved in 2013 as Nesina/Vipidia, and marketed by Takeda Pharmaceutical Company) Trelagliptin (approved for use in Japan as Zafatek/Wedica in 2015) Omarigliptin (MK-3102; approved as Marizev in Japan in 2015, having been developed by Merck & Co. In November 2015, Sheu and colleagues showed that omarigliptin could be used once-weekly and was generally well tolerated throughout the base and extension studies) Evogliptin (approved as Suganon/Evodine for use in South Korea) Gosogliptin (approved as Saterex for use in Russia) Dutogliptin (PHX- 1149; free base being developed by Phenomix Corporation. In a phase III trial as of April 2010) Neogliptin Retagliptin (SP-2086; approved in China) Denagliptin Cofrogliptin (HSK- 7653; compound 2) Fotagliptin Prusogliptin Cetagliptin (CGT 8012) Berberine, an alkaloid found in plants of the genus Berberis (the "barberry"), inhibits DPP-4, which may at least partly explains the chemical's antihyperglycemic activity.
== Phone intercepts == In September 2008, Georgia presented to the public recordings of intercepted phone calls made on 7 August by Ossetian border guards on a Georgian cellular network, which were then independently translated from the original Ossetian language by The New York Times. The recordings, allegedly proving that entry of Georgian troops into Tskhinvali was preceded by movement of part of a Russian armoured regiment into South Ossetia nearly a day earlier, were reviewed and assessed as valid by senior American government and military officials. According to a call recorded at 3:52 am on 7 August, a South Ossetian servicemen at the tunnel with the surname Gassiev was asked by a supervisor at the headquarters if the armor had arrived, to which he replied: "The armor and people." The guard also said that the people had gone through, while "they had already arrived" 20 minutes earlier. Gassiev told the supervisor in the first call at 3:41 am that an inspection of military vehicles inside the tunnel had been requested by the Russian colonel, but Gassiev did not know the exact identity of the colonel. Gassiev reported the exit of armored vehicles from the tunnel to the supervisor at 3:52 am. Authenticity of the calls was not questioned by Russia. Colonel Andrei Kazachenko who was mentioned in the recording, belonged to the 135th Motorized Rifle Regiment, according to Russian media reports after the war.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.